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During FU one patient had confirmed relapse (18 month after 
RT) – (Phoenix+biopsy) and was treated with salvage BT. 
 Conclusion: Obtained results permit us to form conclusion 
that CK based radioablation of low and intermediate risk PC 
patients is an effective treatment modality allowing for OTT 
shrinkage and significant reduction of adverse effects. 
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Not compliant RT of HNC patient is usually understood as a 
violation of dose-time parameters of less or more than 10%, 
respectively. For the purpose of this study:  
A. the overall treatment time (OTT) prolonged more 
than 5 days due to gap(s) in RT is recognized as a 
non-compliant;  
B. original radiobiological explanation hypothesis of 
Gap-Position Phenomenon (GPP) discovered by 
Skladowski K. et al. 1994, 1998) is proposed;  
C. TCP rates are estimated according to Fowler 
methodology. 
Ad A. During current conventional fractionation RT about 10-
15% of patients have experienced the significant prolongation 
of OTT. All these are happen due to and have taken in 
average: random reasons (55%) 5 days, unexpected toxicity 
(20%) 10 days and co-morbidity (25%) 20 days. The average 
length of any gap is 7 days. 
Ad B. For early gap, i.e. 1-19th day of OTT: proangiogenic 
effect of low (<30 Gy) RT dose delivered before the gap is 
evident, therefore reoksygenation of primary tumor hypoxic 
fraction is very expected in spite of evident tumor shrinkage 
due to cell kill of oxic fraction. We hypothesized recruitment 
and repopulation of tumor clonogens over the gap and 
number of tumor cells to kill has increased. As a 
consequence, decreased radiosensitivity is observed when RT 
has returned = loss of LC. For mid gap, i.e. 20-26th day (1 
week only): effect of vascular normalization of 30-40 Gy RT 
dose delivered before the gap is possible and could enhanced 
reoxygenation of residual hypoxic fraction over the gap, what 
means radiosensitivity is increased when RT has returned = 
equal or increased LC. For late gap, i.e. after 26th day: 
effect of vascular damage of high (>40 Gy) RT dose delivered 
before the gap is evident and all residual, alive tumor cells 
become hypoxic, where majority of them are stem allowed to 
fast repopulation over the gap when reoxygenation is possible 
(or later after the treatment completion, if they survive), 
therefore radiosensitivity is decreased when RT has returned 
= loss of LC. From these points of view we should to observe 
clinically different pattern of tumor failures - the rates of 
uncompleted responses (UR) and relapses after complete 
response, and, perhaps, speed of relapse occurrence. 
Ad C. According to Fowler methodology our modeling is 
convinced that SRT could restore the TCP of OTT-protracting 
standard fractionated treatment in aspect of early and late 
gap. 
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At the present time, published clinical results on SBRT exist 
for the following indications: early-stage lung cancer in 
medically inoperable patients or those refusing surgery, lung 
metastases from a large variety of primary cancers, primary 
liver cancer in medically inoperable patients, liver 
metastases (as with lung metastases), pancreas cancer, 
adrenal metastases, primary kidney cancer in medically 
inoperable patients, organ-confined prostate cancer, 
selected intra-thoracic and intra-abdominal lymph node 
metastases, recurrent and primary head and neck cancers, 
spinal tumors, and vertebral bone metastases. Of special 
interest is the current use of SBRT in prostate cancer, where 
patients enjoy high cure rates with a variety of well-
tolerated existing therapies. In this context, especially for 
low-risk patients, the introduction of high-potency SBRT 
could constitute a threat to good outcome in a disease where 
improvements in both disease-free survival and tolerance are 
unlikely. Yet existing treatments are far from perfect. For 
example, conventionally fractionated high dose intensity-
modulated radiation therapy is both expensive for payers and 
inconvenient for patients. Numerous reports with limited 
follow-up show that 5-fraction SBRT for low-risk prostate 
cancer positively addresses both complaints. Using dose 
regimens that are less potent than those used for tumors in 
other sites, prostate SBRT results in excellent clinical 
outcomes compared with other standard treatments in a 
convenient and cost-effective manner. Would SBRT/SRT 
become a standard irradiation method for radiocurable 
tumors and what should they have a bio-clinical 
characteristics? 
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